Skip to content
中文产业新闻评分63Chinese source

艾力斯伏美替尼海外FURVENT三期未达主要终点，合作方ArriVent美股单日暴跌近50%

出海临床试验遇挫，艾力斯伏美替尼海外III期临床未达终点，美股合作方股价单日暴跌近50%

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.